New antisense oligonucleotide therapies reach first base in ALS

被引：8
|
作者：
Lopez, Elia R. [1 ]
Borschel, William F. [1 ]
Traynor, Bryan J. [1 ,2 ]
机构：
[1] NIH, Therapeut Dev Branch, Natl Ctr Adv Translat Sci, Rockville, MD 20852 USA
[2] NIA, Lab Neurogenet, NIH, Bethesda, MD 20892 USA
来源：
NATURE MEDICINE | 2022年 / 28卷 / 01期
基金：
美国国家卫生研究院;
关键词：
HEXANUCLEOTIDE REPEAT; SHAM CONTROL; NUSINERSEN; C9ORF72;
D O I：
10.1038/s41591-021-01629-7
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Two studies highlight the evolution of antisense oligonucleotide therapy for amyotrophic lateral sclerosis, offering hope for an effective treatment.
引用
收藏
页码：25 / 27
页数：3
相关论文
共 50 条
  • [41] The Dutch Center for RNA Therapeutics: a center to develop antisense oligonucleotide therapies for patients with nano-rare mutations
    Lauffer, Marlen C.
    Aartsma-Rus, Annemieke
    Collin, Rob W. J.
    Elgersma, Ype
    van Roon-Mom, Willeke
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 665 - 665
  • [42] WVE-004, an investigational stereopure antisense oligonucleotide for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)
    Liu, Yuanjing
    Andreucci, Amy
    Iwamoto, Naoki
    Yin, Yuan
    Yang, Hailin
    Liu, Fangjun
    Patil, Saurabh
    Mohapatra, Susovan
    Purcell-Estabrook, Erin
    Taborn, Kristin
    Dale, Elena
    Vargeese, Chandra
    NEUROLOGY, 2021, 96 (15)
  • [43] New Gene Therapies Hold Promise for Alzheimer's, ALS
    Davidson, Robert
    US PHARMACIST, 2020, 45 (01) : 5 - 5
  • [44] Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy
    Matsuo, Masafumi
    JMA JOURNAL, 2021, 4 (03): : 232 - 240
  • [45] Base-modified aptamers obtained by cell-internalization SELEX facilitate cellular uptake of an antisense oligonucleotide
    Tanaka, Keisuke
    Okuda, Takumi
    Kasahara, Yuuya
    Obika, Satoshi
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2021, 23 : 440 - 449
  • [46] New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy
    Aoki, Yoshitsugu
    Nagata, Tetsuya
    Takeda, Shin'ichi
    JOURNAL OF ADVANCED COMPUTATIONAL INTELLIGENCE AND INTELLIGENT INFORMATICS, 2012, 16 (04) : 521 - 526
  • [47] Individualized Antisense Oligonucleotide Therapies: How to Approach the Challenge of Manufacturing These Oligos from a Chemistry, Manufacturing, and Control-Regulatory Standpoint
    Lemaitre, Marc M.
    NUCLEIC ACID THERAPEUTICS, 2022, 32 (02) : 101 - 110
  • [48] Emerging directions in ALS therapeutics: Palliative therapies at the advent of the twenty-first century
    Brooks, BR
    CLINICAL NEUROSCIENCE, 1996, 3 (06) : 386 - 392
  • [49] FACILE REMOVAL OF NEW BASE PROTECTING GROUPS USEFUL IN OLIGONUCLEOTIDE SYNTHESIS
    SCHULHOF, JC
    MOLKO, D
    TEOULE, R
    TETRAHEDRON LETTERS, 1987, 28 (01) : 51 - 54
  • [50] A new delivery system for antisense therapy: PLGA microspheres encapsulating oligonucleotide/polyethyleneimine solid complexes
    De Rosa, G
    Bochot, A
    Quaglia, F
    Besnard, M
    Fattal, E
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 254 (01) : 89 - 93
12345